Investment analysts at Leerink Partnrs increased their Q4 2024 earnings estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, January 28th. Leerink Partnrs analyst ...
Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.48% to $672.98 Friday, on what proved to be an all-around grim ...
On January 29, 2025, the Federal Circuit issued paired decisions addressing Samsung Bioepis’s (“SB”) and Formycon AG’s ...
San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...
Plainview-Old Bethpage John F. Kennedy High School has announced that (POBJFKHS) senior Chloe Lee has been recognized as a ...
After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...
Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit ...
Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target cut by research analysts at Piper Sandler from $1,195.00 to $1,013.00 in a report issued on Monday,Benzinga reports. The ...
That scientific creativity helped propel her to being named a top 40 finalist in the 84th Regeneron Science Talent Search — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback